Arming phages with heterologous effectors paves the way for successful UTI treatment

FHS
July 24, 2023
12:11 pm

Study demonstrated how phage can be engineered to produce bacteriocins and cell wall hydrolases as antimicrobial effector genes.

Study finds women lost more of their body weight on average with semaglutide than men

Researchers performed a secondary analysis of the semaglutide treatment effect in people with obesity and heart failure with a preserved left ventricular ejection fraction program

June 26, 2024

Why Andreessen Horowitz’s Julie Yoo sees AI as a ‘leapfrog opportunity’ for healthcare

The Silicon Valley venture firm Andreessen Horowitz in recent years has been investing heavily in healthcare and biotech, guided by its well-known mantra that “software

October 6, 2023

Sanofi and Regeneron’s Dupixent scores second win in Phase III COPD trial

Share this article Dupixent is an interleukin-4 receptor alpha antagonist monoclonal antibody. Image Credit: Net Vector / Shutterstock. Sanofi and Regeneron have reported positive interim

November 27, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.